GovWire

Consultation outcome: Consultation on proposal to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies

Medicines Healthcare Products Regulatory Agency

July 20
08:49 2022

Detail of outcome

A consultation document which summarises the proposal on the prescription only (POM) to pharmacy (P) reclassification of Gina 10 microgram vaginal tablets containing estradiol hemihydrate for the treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women aged 50 years and above, who have not had a period for at least 1 year, was posted on the GOV.UK website on 2 February. The deadline for comments was 23 February 2022.

Original consultation

Summary

Public consultation on a set of proposals to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies.

This consultation ran from
to

Consultation description

Gina 10 microgram vaginal tablets are used for the treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women aged 50 years and above, who have not had a period for at least 1 year and are currently licensed as a prescription only medicine. We propose to make it available in pharmacies.

Gina 10 microgram vaginal tablets contain estradiol, which is a female hormone. They are a form of low dose local hormone replacement therapy. Inserted into the vagina they act locally in the vagina. Locally acting medicines containing estradiol will still be available on prescription from GPs.

Women will have a choice in where they obtain supply of this medicine from, either on prescription or from pharmacies and may opt to switch between methods of supply.

We consider that this product may be available as a Pharmacy (P) medicine.

The Commission on Human Medicines has advised that this product can be available as a Pharmacy (P) medicine.

We want to know what you think about this change.

Please use this form to tell us your views.

The deadline for comments is 23 February 2022.

Below you will find:

  • A summary of the proposed change and the background
  • A copy of the proposed patient information leaflet, label, and pharmacy checklist if the change goes ahead
  • A form for your response

Documents

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: